Related Experiment Video
Updated: Sep 17, 2025
Establishment and Culture of Patient-Derived Breast Organoids
Published on: February 17, 2023
Multicenter study correlating molecular characteristics and clinical outcomes of cancer cases with patient-derived
Paloma Navarro1,2,3,4, Tatiana P Grazioso1,2,3,4, Arantzazu Barquín1,2,3,4
1Laboratory of Innovation in Oncology, Genitourinary, Gynecological and Skin Cancer Unit, HM Clara Campal Comprehensive Cancer Centre (CIOCC) MADRID. Sanchinarro HM University Hospital, HM Hospitals, Madrid, Spain.
Background:
3D-spatial interaction between cancer cells influences tumor behavior, making it essential to replicate tumor structures for predicting patient outcomes.
Methods:
We collected data from three multicenter prospective studies to evaluate the ability to establish Patient-Derived Organoids (PDOs) from different biological samples and timepoints, correlating their characteristics and drug sensitivity with clinical outcomes.
Results:
From 184 patients (17 tumor types), 249 samples were collected: 149 (59.8%) from tumor tissue, 61 (24.5%) from peritoneal fluids, 39 (15.7%) from peripheral blood. Success rates for PDO establishment were 39.5%, 34.4%, and 25.6%, respectively. PDOs reproduced pathological and immunohistochemical patterns of source tumors, with pathogenic variants confirmed in 84% (21/25). In a series of 13 baseline and sequential PDOs from 9 patients undergoing treatment, responses to therapy mirrored patient responses during therapy.
Conclusions:
PDOs preserve tumor features, reflect disease progression, and predict treatment responses, providing valuable models to complement molecular testing in precision medicine.
